An open-label investigator sponsored trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of Fovista (Anti-PDGF-B pegylated aptamer) and Anti-VEGF therapy (Lucentis, Avastin or Eylea in subjects with neovascular age-related macular degeneration.
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2015
At a glance
- Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- 18 Feb 2015 Initial results were presented at the 12th Annual Bascom-Palmer Eye Institute Angiogenesis, Exudation, and Degeneration Meeting, according to an OphthoTech Corporation media release.
- 24 Jul 2014 New trial record